The Role of Programmed Cell Death 1/Programmed Death Ligand 1 (PD-1/PD-L1) Axis in Sepsis-Induced Apoptosis

被引:0
|
作者
Coman, Oana [1 ]
Grigorescu, Bianca-Liana [2 ]
Hutanu, Adina [3 ,4 ]
Bacarea, Anca [5 ]
Vasiesiu, Anca Meda [6 ]
Fodor, Raluca Stefania [2 ]
Stoica, Florin [7 ]
Azamfirei, Leonard [2 ]
机构
[1] Univ Med Pharm Sci & Technol George Emil Palade, Dept Simulat Appl Med, Targu Mures 540142, Romania
[2] Univ Med Pharm Sci & Technol George Emil Palade, Dept Anaesthesiol & Intens Therapy, Targu Mures 540142, Romania
[3] Univ Med Pharm Sci & Technol George Emil Palade, Dept Lab Med, Targu Mures 540142, Romania
[4] Univ Med Pharm Sci & Technol George Emil Palade, Ctr Adv Med & Pharmaceut Res, Immunol, Targu Mures 540142, Romania
[5] Univ Med Pharm Sci & Technol George Emil Palade, Dept Pathophysiol, Targu Mures 540142, Romania
[6] Univ Med Pharm Sci & Technol George Emil Palade, Dept Infect Dis, Targu Mures 540142, Romania
[7] Emergency Cty Hosp, Clin Internal Med 2, Targu Mures 540136, Romania
来源
MEDICINA-LITHUANIA | 2024年 / 60卷 / 07期
关键词
sepsis; septic shock; programmed cell death; apoptosis; lymphocytes; CD4+lymphocytes; CD8+lymphocytes; PD-1/PD-L1; axis; SOFA; APACHE II; MORTALITY;
D O I
10.3390/medicina60071174
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Sepsis involves a dysregulated host response, characterized by simultaneous immunosuppression and hyperinflammation. Initially, there is the release of pro-inflammatory factors and immune system dysfunction, followed by persistent immune paralysis leading to apoptosis. This study investigates sepsis-induced apoptosis and its pathways, by assessing changes in PD-1 and PD-L1 serum levels, CD4+ and CD8+ T cells, and Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE II) severity scores. Materials and Methods: This prospective, observational, single-centre study enrolled 87 sepsis patients admitted to the intensive care unit at the County Emergency Clinical Hospital in T & acirc;rgu Mures, Romania. We monitored the parameters on day 1 (the day sepsis or septic shock was diagnosed as per the Sepsis-3 Consensus) and day 5. Results: Our study found a statistically significant variation in the SOFA score for the entirety of the patients between the studied days (p = 0.001), as well as for the studied patient groups: sepsis, septic shock, survivors, and non-survivors (p = 0.001, p = 0.003, p = 0.01, p = 0.03). On day 1, we found statistically significant correlations between CD8+ cells and PD-1 (p = 0.02) and PD-L1 (p = 0.04), CD4+ and CD8+ cells (p < 0.0001), SOFA and APACHE II scores (p < 0.0001), and SOFA and APACHE II scores and PD-L1 (p = 0.001 and p = 0.01). On day 5, we found statistically significant correlations between CD4+ and CD8+ cells and PD-L1 (p = 0.03 and p = 0.0099), CD4+ and CD8+ cells (p < 0.0001), and SOFA and APACHE II scores (p < 0.0001). Conclusions: The reduction in Th CD4+ and Tc CD8+ lymphocyte subpopulations were evident from day 1, indicating that apoptosis is a crucial factor in the progression of sepsis and septic shock. The increased expression of the PD-1/PD-L1 axis impairs costimulatory signalling, leading to diminished T cell responses and lymphopenia, thereby increasing the susceptibility to nosocomial infections.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 219 - 219
  • [2] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1125 - 1125
  • [3] Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer
    Neelima Vidula
    Christina Yau
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2021, 187 : 387 - 395
  • [4] Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer
    Vidula, Neelima
    Yau, Christina
    Rugo, Hope S.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 387 - 395
  • [5] Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
    Abaza, Abdelrahman
    Idris, Faten Sid
    Shaikh, Humna Anis
    Vahora, Ilma
    Moparthi, Kiran Prasad
    Al Rushaidi, Majdah T.
    Muddam, Meghana Reddy
    Obajeun, Omobolanle A.
    Jaramillo, Arturo P.
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [6] Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
    T. Mocan
    Z. Sparchez
    R. Craciun
    C. N. Bora
    D. C. Leucuta
    Clinical and Translational Oncology, 2019, 21 : 702 - 712
  • [7] Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
    Mocan, T.
    Sparchez, Z.
    Craciun, R.
    Bora, C. N.
    Leucuta, D. C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 702 - 712
  • [8] A NOVEL ROLE FOR PROGRAMMED CELL DEATH RECEPTOR LIGAND-1 (PD-L1) IN SEPSIS-INDUCED GASTROINTESTINAL DYSFUNCTION
    Wu, Y.
    Huang, X.
    Chung, C.
    Ayala, A.
    SHOCK, 2014, 41 : 21 - 21
  • [9] In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
    Reddy, Vishwanatha R. A. P.
    Mwangi, William
    Sadigh, Yashar
    Nair, Venugopal
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [10] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A